Protalix BioTherapeutics (PLX) Work In Process (2012 - 2026)
Protalix BioTherapeutics (PLX) posted quarterly Work In Process of $9.1 million for Q1 2026, up 13.51% year-over-year from $8.0 million in Q1 2025, and down 3.11% quarter-over-quarter from $9.4 million in Q4 2025.
Protalix BioTherapeutics (PLX) Work In Process (2012 - 2026) Analysis & Trends
Protalix BioTherapeutics' Work In Process history runs 9 years deep, the most recent figure standing at $9.1 million for Q1 2026.
- In Q1 2026, Work In Process rose 13.51% year-over-year to $9.1 million; the TTM figure through Mar 2026 stood at $9.1 million (up 13.51% YoY), while the FY2025 annual figure was $9.4 million, down 16.63% from the prior year.
- Work In Process for Q1 2026 stood at $9.1 million, down from $9.4 million in the prior quarter.
- The five-year high for Work In Process was $12.3 million in Q3 2024, with the low at $1.5 million in Q1 2023.
- The 5-year median for Work In Process is $8.1 million (2025), against an average of $7.0 million.
- The sharpest annual moves came in 2024 and 2025: Work In Process soared 498.11% in 2024, then plunged 56.29% in 2025.
- Protalix BioTherapeutics' Work In Process stood at $2.7 million in 2022, then jumped by 238.13% to $9.1 million in 2023, then climbed by 24.19% to $11.2 million in 2024, then dropped by 16.63% to $9.4 million in 2025, then dropped by 3.11% to $9.1 million in 2026.
- Business Quant data shows PLX's Work In Process at $9.1 million in Q1 2026, $9.4 million in Q4 2025, and $5.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | Protalix BioTherapeutics | 190.37 Mn | 149.71 Mn | 12.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 8.25 Mn |
| Mar 31, 2026 | 9.08 Mn |
| Dec 31, 2025 | 9.38 Mn |
| Sep 30, 2025 | 5.36 Mn |
| Jun 30, 2025 | 8.14 Mn |
| Mar 31, 2025 | 8.00 Mn |
| Dec 31, 2024 | 11.25 Mn |
| Sep 30, 2024 | 12.25 Mn |
| Jun 30, 2024 | 10.87 Mn |
| Mar 31, 2024 | 9.17 Mn |
| Dec 31, 2023 | 9.06 Mn |
| Sep 30, 2023 | 9.12 Mn |
| Jun 30, 2023 | 3.32 Mn |
| Mar 31, 2023 | 1.53 Mn |
| Dec 31, 2022 | 2.68 Mn |
| Sep 30, 2022 | 2.62 Mn |
| Jun 30, 2022 | 3.30 Mn |
| Mar 31, 2022 | 3.37 Mn |
| Dec 31, 2021 | 3.26 Mn |
| Sep 30, 2021 | 3.51 Mn |